NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
ANVISA issues CGMP to Concord Biotech’s Unit I
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)